Search Results
Your search for The ASCO matches 21148 pages
Showing 7651 - 7700Hypercoagulability in Critically Ill Patients With COVID-19: Where Do We Stand?
“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” ―Hippocrates The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Connors...
AACR 2020: Final Overall Survival Results From the Phase III EMBRACA Trial
New data from the phase III EMBRACA trial showed the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib did not produce a statistically significant overall survival benefit for patients with locally advanced or metastatic HER2-negative germline BRCA-mutated breast cancer. Most patients...
ASCO, Conquer Cancer Honor Leaders in Cancer Care With 2020 Special Awards
ASCO and Conquer Cancer, the ASCO Foundation®, are proud to recognize the winners of ASCO’s 2020 Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. David A. Karnofsky Memorial Award...
Robert L. Coleman, MD, Named Chief Scientific Officer for the US Oncology Network
On March 31, 2020, the US Oncology Network (The Network) named cancer researcher Robert L. Coleman, MD, FACOG, FACS, as its new Chief Scientific Officer. In this role, Dr. Coleman will be the senior-most clinician scientist on The US Oncology Network leadership. Dr. Coleman, who most recently...
NCI Awards $14.5 Million Grant for Immunotherapy Research
A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center, has earned a 5-year, $14.5 million award from the National Cancer Institute (NCI) to expand a promising immunotherapy platform. Funded through the NCI’s Program Project Grant, this 5-year grant will fund five...
Smilow Cancer Hospital and Yale Cancer Center Appoint Deputy Chief Medical Officer
Mehra Golshan, MD, MBA, FACS, has been appointed the inaugural Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center, Professor of Surgery at Yale School of Medicine, and Interim Director of the Breast Center at Smilow Cancer Hospital. As Deputy Chief...
AMA Highlights Mental Health Resources for Physicians During COVID-19 Pandemic
Earlier this month, the American Medical Association (AMA) announced resources available to help physicians cope with increased levels of distress and anxiety during the coronavirus disease 2019 (COVID-19) pandemic. These resources build on the AMA’s efforts to ensure physicians and other...
Virtual Appointments Help Patients With Cancer Continue Care During COVID-19 Health Crisis
Texas Oncology recently announced a major expansion of its telemedicine services to allow patients to schedule virtual visits with more than 400 physicians and 150 advanced practice providers throughout the statewide cancer care practice. Through this expanded approach, launched earlier this month, ...
FDA Accelerates Development of Novel Therapies for COVID-19
The U.S. Food and Drug Administration (FDA) has implemented a program to expedite the development of potentially safe and effective life-saving treatments. The program, known as the Coronavirus Treatment Acceleration Program (CTAP), is using every tool at the agency’s disposal to bring new...
Adapting Adjuvant Endocrine Therapy by Patient Age and Risk
The individualization and optimization of adjuvant endocrine therapy for breast cancer are important and not always simple. Guidance on this issue was offered at the 2020 Miami Breast Cancer Conference by Joyce O’Shaughnessy, MD, the Celebrating Woman Chair in Breast Cancer Research at Baylor...
Radon Exposure: A Leading Environmental Cause of Cancer Mortality in the United States
The Environmental Protection Agency (EPA) has concluded that about 21,000 people die each year of lung cancer related to radon gas exposure, making it the second leading cause of lung cancer death in the United States. Although the EPA and various other organizations, including the National Radon ...
PD-1 Inhibition in Mismatch Repair–Deficient/Microsatellite Instability–High Cancers Other Than Colorectal Cancer
Mismatch repair (MMR)-deficiency and consequently high DNA microsatellite instability (MSI-H) are associated with high tumor mutational burden. A high mutational load increases the potential number of neoantigens that can be presented by the tumor cell and recognized by host lymphocytes. Detection...
Gut Bacterial Diversity: A Marker or Driver of Outcomes After Hematopoietic Cell Transplantation?
Previous single-center studies have linked the gut microbiota (via stool sample analysis) to outcomes after hematopoietic cell transplantation (HCT), such as overall mortality, transplant-related mortality, graft-vs-host disease, and graft-vs-host–related mortality.1-4 Although intriguing, these...
Selected ASH Abstracts on Novel Treatments for Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for patients with non-Hodgkin lymphomas (NHLs). For full...
How CRISPR-Cas9 Gene Editing May Improve the Effectiveness of Cellular Therapeutics in Patients With Cancer
The results from the first in-human phase I clinical trial in the United States evaluating CRISPR-Cas9–edited T cells in patients with advanced cancer has shown that the therapy is both feasible and safe, representing a big step forward in the potential of using gene editing to boost the natural...
ASCENT Study Halted: Efficacy Shown Across Multiple Study Endpoints in Triple-Negative Breast Cancer
The phase III confirmatory ASCENT study of the antibody drug-conjugate sacituzumab govitecan will be stopped based on efficacy across multiple study endpoints following unanimous recommendation from the independent data safety monitoring committee, according to a news release issued earlier this...
Beyond CDK4/6 Inhibitors: What Subsequent Treatment Is Best?
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have changed the natural history of hormone receptor–positive metastatic breast cancer. While median progression-free survival on these drugs is approximately 27 months, the disease eventually progresses and clinicians must choose a subsequent ...
More Antibody-Drug Conjugates on the Horizon for Breast Cancer
Novel antibody-drug conjugates that target actionable cell-surface markers in metastatic breast cancer will soon expand the utility of the class that already includes ado-trastuzumab emtansine (T-DM1), according to two speakers at the 2020 Miami Breast Cancer Conference. These new agents were...
Do HIV Positivity and Autoimmune Disease Preclude Treatment With Checkpoint Inhibitors?
Can patients with cancer and preexisting autoimmune disorders safely benefit from immunotherapy? The answer has been unclear, with only retrospective studies and anecdotal reports guiding oncologists. This subpopulation of patients has largely been excluded from clinical trials out of concerns over ...
What’s the Current Status of Neoadjuvant Immunotherapy?
For several tumor types, can the successes achieved with immunotherapy in the metastatic and adjuvant settings be replicated in the neoadjuvant setting? An explosion in clinical trials—with more than 300 listed on ClinicalTrials.gov—point to “yes.” “The neoadjuvant use of immunotherapy is of great ...
Upfront Apalutamide Delays Time to Second Progression in Metastatic Castration-Sensitive Prostate Cancer
The addition of apalutamide to androgen-deprivation therapy (ADT) reduced the risk of second disease progression or death (PFS2) by 34% vs ADT alone in patients with metastatic castration-sensitive prostate cancer, in a post hoc analysis of the phase III TITAN trial presented at the 2020...
Merry-Jennifer Markham, MD, FACP, FASCO, Rose From Humble Beginnings to a Leadership Role in Oncology
Merry-Jennifer Markham, MD, FACP, FASCO, grew up in Fort White, Florida, a rural speck on the map in the northern part of the state. Fort White is home to the Ichetucknee River and Springs, a crystal-clear natural wonder known only to the locals until 1972, when it was declared a National Natural...
ASCO Resources on COVID-19 for the Oncology Community
The worldwide spread of the novel coronavirus (COVID-19) presents unprecedented challenges and uncertainty to the cancer care delivery system. ASCO has been actively monitoring and responding to the pandemic to ensure that accurate information is readily available to clinicians and their patients. ...
Conquer Cancer Researchers Remember Jane C. Wright, MD, FASCO
It’s 1964 in Chicago. Seven forward-thinking oncologists gather to brainstorm what will become the American Society of Clinical Oncology (ASCO). Among the group is Jane C. Wright, MD, FASCO, the only woman and African American among ASCO’s founders. It’s time for the 2011 ASCO Annual Meeting in...
FDA’s Draft Guidance Will Improve Evidence Base for Older Adults With Cancer
ASCO commends the U.S. Food and Drug Administration (FDA) for releasing draft guidance that encourages inclusion of older adults in clinical trials of drugs for the treatment of cancer. The guidance emphasizes the importance of including adults aged 75 or older in clinical trials to better enable...
It’s T Time for Peripheral T-Cell Lymphoma, a Much-Neglected Disease
The lymphomas are an incredibly complex assemblage of neoplastic diseases. They are not one disease, and, at least based on the World Health Organization (WHO) Classification of Tumors published in 2017, they represent a collection of approximately 80 different malignancies, a number that will...
AACR Annual Meeting to Be Held in Two-Part Virtual Platform
Earlier this month, the American Association for Cancer Research (AACR) announced that the group’s Annual Meeting would be held in a two-part virtual format and not in person. Instead, segments of the meeting program will be presented in late April and in June 2020. The decision was made not to...
AACR Provides Scientific Expertise to Assist FDA’s Public Health Initiative
The American Association for Cancer Research (AACR) is working with the U.S. Food and Drug Administration (FDA) to advance the FDA’s public health initiative called Project Renewal. Launched in October 2018 by the FDA’s Oncology Center for Excellence (OCE), Project Renewal has an ambitious goal to...
EXPECT INTEREST AND QUESTIONS ABOUT STATINS AND METFORMIN
A study showing that statins used alone or in combination with metformin was associated with reduced prostate cancer mortality and all-cause mortality among men with high-risk prostate cancer may raise more questions about these already commonly used drugs.1 “Metformin is the first-line therapy for ...
Statins With or Without Metformin Are Associated With Increased Survival in Patients With High‑Risk Prostate Cancer
A population-based retrospective cohort study involving 12,700 patients found that men with high-risk prostate cancer who took a statin alone or in combination with metformin had reduced all-cause and prostate cancer–specific mortality. The associations between the medications and reduced...
A Clinical Trial Saved My Life
In the fall of 2009, I began experiencing some abdominal discomfort, pain in my right shoulder, and severe fatigue that were easily explained away as the result of gallstones and by my career as a paramedic. I had many of the risk factors for gallbladder disease, and both my mother and sister...
Inoperable Carcinoma of the Breast
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The X-Ray Era: 1901–1915 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Dr. Burns and The Burns Archive. To view ...
Chemotherapy and the Sweat Lodge
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Unnecessary Barrier to Blood Donation for British Nationals?
I read with great interest Jo Cavallo’s article “Maintaining Blood Donations During the COVID-19 Pandemic”. My wife and I have been British residents in the United States for over 6 years and are frustrated that we cannot donate blood, especially during this raging global COVID-19 pandemic, when...
NIH Launches $1 Million Competition to Target Disease Diagnostics
The National Institutes of Health (NIH) has launched the $1 million Technology Accelerator Challenge to spur the design and development of noninvasive, handheld, digital technologies to detect, diagnose, and guide therapies for diseases with high global and public health impact. The challenge is...
Fox Chase Cancer Center Announces New Name and Recertification for Palliative Care Program
To more accurately reflect the mission and vision of the program, Fox Chase Cancer Center recently announced that the name of the Pain and Palliative Care Program has been changed to the Supportive Oncology and Palliative Care Program (SOPCP). The program has also received, for the third time, the ...
Joseph C. Alvarnas, MD, on the Increased Risk of Side Effects for Patients With Cancer and COVID-19
Joseph C. Alvarnas, MD, of the City of Hope National Medical Center, discusses the patients with cancer who are at an increased risk for developing serious complications from COVID-19, including those receiving bone marrow or stem cell transplants and CAR-T cell therapy, and what they can do to...
Helping Patients to Feel Informed About Goals and Adverse Effects of Cancer Treatments
How confident should oncologists be that their patients feel adequately informed about the adverse effects of their cancer treatment? A recent study by Shaverdian et al,1 reported in the Journal of Oncology Practice and reviewed in this issue of The ASCO Post, found that 18% of 403 patients felt...
Gut Microbiota Emerging as Key Player in Response to Immunotherapy
The microbiome—and the foods that feed it—is emerging as an important determinant of a patient’s response to immunotherapy. Much of the research in this area comes from The University of Texas MD Anderson Cancer Center, as described at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium by...
Intermittent Dawn-to-Sunset Fasting and Anticancer Serum Proteome
In a small study published in the Journal of Proteomics, Ayse Leyla Mindikoglu, MD, MPH, and colleagues found that dawn-to-sunset fasting was associated with proteins that were protective against cancer as well as obesity, diabetes, metabolic syndrome, inflammation, and some neurologic disorders...
Budwig Diet
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on the Budwig...
Vitamin D and Lymphoma: An Apparent Benefit, but Further Study Required
Vitamin D is a steroid-like hormone involved primarily in human calcium homeostasis. Obtained through sun exposure as well as food and dietary supplements,1 vitamin D in humans is metabolized in the liver and kidneys to its active form, 1,25-dihydroxyvitamin D (1,25[OH]2D).2 Other cell types,...
FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer
On April 22, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. Sacituzumab govitecan-hziy is the first...
ACS Releases New Guidance to Help Health-Care Facilities Prepare for Resuming Elective Surgery Past COVID-19 Peak
The American College of Surgeons (ACS) has released a new surgical resource document, “Local Resumption of Elective Surgery Guidance,” as a guide for health-care facilities preparing to resume elective surgery once COVID-19 has peaked in their area. Health-care facilities have been allocating...
David A. Tuveson, MD, PhD, FAACR, Named AACR President-Elect for 2020–2021
The members of the American Association for Cancer Research (AACR) have elected David A. Tuveson, MD, PhD, FAACR, as their President-Elect for 2020–2021. He will officially become President-Elect on April 29, 2020, during the AACR’s Business Meeting of Members. He will assume the presidency in...
FDA Approves Ibrutinib/Rituximab for CLL/SLL
On April 21, the U.S. Food and Drug Administration (FDA) expanded the indication of ibrutinib (Imbruvica) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This review was conducted...
Hope S. Rugo, MD, on Talazoparib for Advanced Solid Tumors: Reduced Hospitalization and Supportive Care
Hope S. Rugo, MD, of the University of California, San Francisco, discusses an integrated analysis of five clinical trials, in phases I through III, for a variety of advanced cancers. Findings show that patients treated with talazoparib monotherapy had lower hospitalization rates (compared to those ...
Sara A. Hurvitz, MD, on Talazoparib vs Chemotherapy for Breast Cancer: Results From the EMBRACA Trial
Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses racial differences in self-reported outcomes of patients with HER2-negative, locally advanced or metastatic breast cancer and a germline BRCA1/2 mutation who received talazoparib vs physician’s choice of chemotherapy...
FDA Authorizes First COVID-19 Test for Patient At-Home Sample Collection
The U.S. Food and Drug Administration (FDA) authorized the first diagnostic test with a home collection option for COVID-19. Specifically, the FDA re-issued the emergency use authorization (EUA) for the Laboratory Corporation of America (LabCorp) COVID-19 RT-PCR Test to permit testing of samples...
Patients May Experience Increased Infections Preceding a Cancer Diagnosis
Patients may experience a greater occurrence of infections in the years preceding a cancer diagnosis, according to results from a study published by Inaida et al in Cancer Immunology Research. “Cancer can develop in an inflammatory environment caused by infections, immunity disruption, exposure to...
